Tom Englund will take over as the new CEO of Surgical Science on October 1, 2024. Tom currently works as COO and Deputy CEO at Instabee. He will succeed the current CEO Gisli Hennermark, who after October 1 will remain in an advisory role until the end of March 2025. Gisli will also continue as a member of the Board of Directors of Surgical Science.

On March 12, 2024, it was announced that Gisli Hennermark, CEO of Surgical Science Sweden AB (publ) since nine years, had informed the Board of Directors that he intended to leave his position. Furthermore, it was announced that Gisli would remain as CEO until the Board of Directors had appointed a new CEO and that he would act as an advisor to the new CEO until March 2025. At the Annual General Meeting on May 16, 2024, Gisli was elected as a member of the Board of Directors of Surgical Science.

The process of finding Gisli's successor has been ongoing since March and has been led by the Chairman of the Board Roland Bengtsson.

Tom Englund holds a Master of Science in Industrial Engineering and Management from Linköping University. Previous experiences include Accenture and Roland Berger, various roles within Atlas Copco where Tom spent seven years based in Stockholm and Shanghai, and Tobii where he worked for twelve years. At Tobii, a leading company in eye tracking, revenues during Tom's tenure grew from around SEK 200 million to SEK 1.4 billion. Tom was CEO of the Tobii Pro business unit and later also Deputy CEO of the Tobii Group. Since 2021, Tom has worked for Instabox, which through a merger with Budbee in 2022 became Instabee, a logistics company in deliveries to parcel lockers and homes with around 1,100 employees and a turnover of approximately SEK 2 billion. Tom is today the COO and Deputy CEO at Instabee.

From his roles, Tom has experience in leading fast-growing high-tech organizations with a focus on profitable growth, developing business models, acquiring and integrating businesses, and scaling and merging organizations in a complex structure and international environment.

Tom will start his employment in Surgical Science on August 19 and will assume the position of CEO on October 1, 2024. Tom has no board assignments except for internal assignments within the Instabee Group.

"In Tom, we have found the next leader for Surgical Science's continued profitable growth. We see great opportunities to scale up the company in the coming years. The digitalization of healthcare is only in its beginnings and Surgical Science's contribution to patient safety through simulation has great growth opportunities. The fact that Gisli will act as an advisor for a period of time enables an efficient transition and for Tom to quickly get to know the business. Tom's leadership skills, organizational know-how, experience of acquisitions and ability to develop business models for an increasing share of software services are some of the qualities that have made the Board of Directors confident that Tom is the right person to lead Surgical Science forward," says Roland Bengtsson, Chairman of the Board of Surgical Science.

"I am grateful for the Board's confidence and feel a great enthusiasm to contribute to Surgical Science's continued growth journey. The company is clearly a world leader in its field and has a strong and important purpose in developing capabilities in surgery and patient safety. I am impressed with the position and the results that have been created so far and I look forward to working together with all professional and committed employees to develop the company further", says Tom Englund, incoming CEO of Surgical Science.

Gothenburg, Sweden, July 1, 2024
Surgical Science Sweden AB (publ)

This press release, in its entirety, is available through the attachment or via:
https://surgicalscience.com/investor-relations/#press-releases

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

For further information, please contact:

Gisli Hennermark, CEO
Telephone: +46-70-420 83 00
E-mail: gisli.hennermark@surgicalscience.com

Anna Ahlberg, CFO
Telephone: +46-70-855 38 35
E-mail: anna.ahlberg@surgicalscience.com

About Surgical Science Sweden AB (publ)

One of the biggest challenges within healthcare globally is reducing injuries incurred during care. Medical education and training are key, especially as a large part of the training can now be performed outside the operating room. Surgical Science is a world leader in the development of virtual reality simulators for evidence-based training. The simulators enable surgeons and other medical specialists to train and improve their psycho-motor skills and instrument handling before entering the clinical environment. Alongside its own products, Surgical Science works with simulation solutions for medical device companies that develop instruments for clinical use, such as robotic surgery.

Surgical Science has approximately 260 employees. The company is headquartered in Gothenburg, Sweden and also has operations in Tel Aviv, Israel, as well as in Stockholm, Sweden and in Seattle and Cleveland, US. Through sales offices in the US and China as well as a global network of distributors, Surgical Science maintains a presence in most markets. Shares in Surgical Science Sweden AB (publ) are traded on Nasdaq First North Growth Market. Certified Adviser is Carnegie Investment Bank AB (publ).

This information is information that Surgical Science Sweden AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-07-01 08:30 CEST.

Attachments

Tom Englund appointed new CEO of Surgical Science

© Modular Finance, source Nordic Press Releases